Get the Stockscreener App
3.11
55.50%
1.11
Esperion Therapeutics Inc stock is traded at $3.11, with a volume of 182.07M.
It is up +55.50% in the last 24 hours and up +19.16% over the past month.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
See More
Previous Close:
$2.00
Open:
$3.13
24h Volume:
182.07M
Relative Volume:
22.16
Market Cap:
$800.53M
Revenue:
$403.14M
Net Income/Loss:
$-22.68M
P/E Ratio:
-14.84
EPS:
-0.2095
Net Cash Flow:
$-13.09M
1W Performance:
+62.83%
1M Performance:
+19.16%
6M Performance:
+4.71%
1Y Performance:
+216.06%
1-Day Range:
$3.10
$3.14
1-Week Range:
$1.80
$3.14
52-Week Range:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.11 | 800.53M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
16.62 | 52.51B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
114.16 | 48.01B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.38 | 41.69B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.95 | 40.70B | 17.52B | 1.58B | 1.06B | 1.3428 |
UTHR
United Therapeutics Corp
|
570.40 | 24.21B | 3.18B | 1.33B | 1.04B | 27.90 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Therapeutics, Inc. $ESPR is AIGH Capital Management LLC's 10th Largest Position - MarketBeat
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga
Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion - Law360
Piper Sandler Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next - TechStock²
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpShould You Buy? - MarketBeat
The Biotech Growth Trust plc Archimed to acquire Biog Portfolio Company, Esperion Therapeutics. - marketscreener.com
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR) - GlobeNewswire Inc.
Esperion agrees to $1.1 billion ARCHIMED buyout - TipRanks
Investors Buy High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - MarketBeat
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - ChartMill
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal - Yahoo Finance
H.C. Wainwright Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Ann Arbor drugmaker to be acquired by French investor - Crain's Detroit Business
Archimed to Acquire Biotech Growth Trust Portfolio Co Esperion for $1 Billion - marketscreener.com
H.C. Wainwright cuts Esperion stock rating on Archimed buyout By Investing.com - Investing.com Canada
Archimed to take Esperion Therapeutics private in $1.1 billion deal - Reuters
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by HC Wainwright to Neutral - MarketBeat
An unknown funds, managed by ArchiMed SAS entered into a definitive agreement to acquire Esperion Therapeutics, Inc.. - marketscreener.com
ESPR Rallies As Royalty Deal Fuels Corstasis Expansion - StocksToTrade
Archimed to acquire Esperion Therapeutics for $1 billion By Investing.com - Investing.com Canada
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
ESPR Stock In Focus As Royalty Deal Fuels Corstasis Acquisition - timothysykes.com
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - Yahoo Finance
Esperion Stock Pops On Billion-Dollar ARCHIMED Buyout - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs - Stock Titan
Esperion Therapeutics: Board of Directors Has Unanimously Approved the Transaction >ESPR - Moomoo
ARCHIMED to acquire Esperion for up to $1.1 billion - Investing.com
ARCHIMED to acquire Esperion for up to $1.1 billion By Investing.com - Investing.com Canada
Archimed to take Esperion Therapeutics private for up to $1.1 billion - marketscreener.com
Archimed privatizará Esperion Therapeutics por hasta 1.100 millones de dólares - TradingView
Esperion to be Acquired by ARCHIMED - GlobeNewswire
#1 Most Undervalued Stock to BUY: 40% Growth, 4x Forward Earnings, and Massive Upside Potential - Moomoo
Rumor Desk: ESPERION PARTNERSHIP WITH BIG PHARMA IN THE WORKS. Stock Price Will Double - Moomoo
Esperion Therapeutics prices $75M public offering - MSN
This $2 Stock Profitable This Year $9 Price Target Analysts See As M&A Target. Has Yearly Billion Dollar Revenue Stream Potential - Moomoo
Esperion Therapeutics soars amid vague takeover speculation - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 6%Here's What Happened - MarketBeat
Esperion to Report First Quarter 2026 Financial Results on May 7 - The Manila Times
First quarter 2026 results set for May 7 as Esperion Therapeutics outlines earnings calendar - Traders Union
Esperion sets May 7 earnings release, 8 a.m. ET webcast - Stock Titan
Is Esperion Therapeutics (ESPR) stock trending lower | Q4 2025: EPS Misses EstimatesCompetitive Risk - Cổng thông tin điện tử Tỉnh Sơn La
Esperion Therapeutics (NASDAQ:ESPR) Shares Cross Below 200 Day Moving AverageHere's What Happened - MarketBeat
Is Esperion Therapeutics (ESPR) stock outperforming similar companies | Q4 2025: EPS Misses ViewsCrowd Trend Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Wasatch Advisors takes 6.1% stake in Esperion Therapeutics (NASDAQ: ESPR) - Stock Titan
Esperion Therapeutics A Takeover Target Say Analysts With Huge Earnings Growth Ahead. Wasatch Doubles Investment - Moomoo
Esperion Therapeutics spotlights 2026 ACC AHA multisociety guideline for dyslipidemia management - Traders Union
What risks should investors watch for Esperion Therapeutics (ESPR) stock (-2.70%) 2026-04-20Pro Level Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Esperion Therapeutics Inc Stock (ESPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Mar 17 '26 |
Sale |
2.72 |
25,578 |
69,547 |
2,172,699 |
| Halladay Benjamin | Chief Financial Officer |
Mar 17 '26 |
Sale |
2.71 |
6,424 |
17,377 |
713,602 |
0.63%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):